2nd Peptide Formulation and Delivery Innovation Summit

Peptide bioavailability has been significantly enhanced in recent years, evidenced by Pfizer developing an optimized formulation for its oral GLP-1 drug danuglipron, AbbVie buying out Nimble Therapeutics for its oral peptide assets and J and J advancing development of its IL-23 receptor antagonist peptide to address the high unmet need for a durable oral option. Additionally, innovative excipient and delivery approaches are making oral administration of peptides a clinical reality, but bottlenecks remain.

Returning to Boston as your premier industry-dedicated forum, the 2nd Peptide Formulation and Delivery Innovation Summit addresses how to overcome unique formulation challenges and accelerate innovative delivery technology applications to progress peptide-based therapeutic pipelines towards patients and commercialization.

Time: 8:00 AM - 5:00 PM

Venue Details: Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United States